Fabrication and Microstructure of ZnO-SiO&lt;sub&gt;2&lt;/sub&gt; Nanoparticles by a Reverse Micelle and Sol-Gel Processing

Kim, Rak Hee; Kim, Jae Won; Park, K.S.; Bae, Dong‐Sik

doi:10.4028/www.scientific.net/msf.510-511.790

Cited by 2 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They can either have an aqueous or a hydrophobic core depending on the drug cargo, and different concentrations of the amphiphilic polymers can be used to fabricate different shapes. 20 Micellar NPs with cargo have been deployed for proof of concept biomedical applications such as cancer and human immunodeficiency virus. 21 In addition to PEG of various molecular weights, and amphiphilic polymers, biodegradable polymers have found a desirable role in biomedical applications because they are readily excreted from the body upon degradation under physiological conditions.…”

Section: Polymeric Nanoparticlementioning

confidence: 99%

Design Considerations and Assays for Hemocompatibility of FDA-Approved Nanoparticles

Saha

Zhen

Erogbogbo

et al. 2019

Semin Thromb Hemost

View full text Add to dashboard Cite

Nanoparticles have numerous biomedical applications including, but not limited to, targeted drug delivery, diagnostic imaging, sensors, and implants for a wide range of diseases including cancer, diabetes, heart disease, and tuberculosis. Although the mode of delivery of the nanoparticles depends on the application and the disease, the nanoparticles are often in immediate contact with the systemic circulation either because of intravenous administration or their ability to enter the bloodstream with relative ease or their longer survival time in circulation. Once in circulation, the nanoparticles may elicit unintended hemostatic and inflammatory responses, and hence the design of nanoparticles for therapeutic applications should take broad hemocompatibility concerns into consideration. In this review, we present the principles underlying the structural and functional design of various classes of nanoparticles that are currently approved by the US Food and Drug Administration, categorize these particles based on their interactions with cardiovascular tissues and ensuing adverse events, and also describe various in vitro assays that may be used evaluate their hemocompatibility.

show abstract

Section: Polymeric Nanoparticlementioning

confidence: 99%